Understanding the molecular interactions of different radical scavengers with ribonucleotide reductase M2 (hRRM2) domain: opening the gates and gaining access
- PMID: 22639080
- DOI: 10.1007/s10822-012-9581-y
Understanding the molecular interactions of different radical scavengers with ribonucleotide reductase M2 (hRRM2) domain: opening the gates and gaining access
Abstract
We employed a combination of molecular docking and dynamics to understand the interaction of three different radical scavengers (SB-HSC21, ABNM13 and trimidox) with ribonucleotide reductase M2 (hRRM2) domain. On the basis of the observed results, we can propose how these ligands interact with the enzyme, and cease the radical transfer step from the di-iron center to TYR176. All the ligands alter the electron density over TYR176, -OH group by forming an extremely stable H-bond with either -NHOH group, or with phenolic hydroxyl group of the ligands. This change in electronic density disrupts the water bridge between TYR176, -OH and the di-iron center, which stops the single electron transfer process from TYR176, -OH to iron. As a consequence the enzyme is inhibited. Another interesting observation that we are reporting is the two stage gate keeping mechanism of the RR active site tunnel. We describe these as the outer Gate-1 controlled by ARG330, and the inner Gate-2 controlled by SER263, PHE240, and PHE236. We also observed a dynamic conformational shift in these residues, the incoming ligands can go through, and interact with the underlying TYR176, -OH group. From the study we found the active-site of hRRM2 is extremely flexible and shows a significant induced fit.
Similar articles
-
Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2.Mol Cancer Ther. 2010 Jun;9(6):1669-79. doi: 10.1158/1535-7163.MCT-10-0023. Epub 2010 May 18. Mol Cancer Ther. 2010. PMID: 20484015 Free PMC article.
-
Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.Biochem Biophys Res Commun. 2006 Feb 10;340(2):428-34. doi: 10.1016/j.bbrc.2005.12.019. Epub 2005 Dec 15. Biochem Biophys Res Commun. 2006. PMID: 16376858
-
Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.Cancer Res. 2003 Mar 1;63(5):980-6. Cancer Res. 2003. PMID: 12615712
-
Radical scavengers as ribonucleotide reductase inhibitors.Curr Top Med Chem. 2012;12(24):2827-42. doi: 10.2174/1568026611212240009. Curr Top Med Chem. 2012. PMID: 23368105 Review.
-
Combination chemotherapy directed at the components of nucleoside diphosphate reductase.Pharmacol Ther. 1985;29(1):111-27. doi: 10.1016/0163-7258(85)90019-1. Pharmacol Ther. 1985. PMID: 3914643 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials